- Home
- CRGX vs AUTL Comparison
CRGX vs AUTL Comparison
Compare CRGX & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- AUTL
- Stock Information
- Founded
- CRGX 2021
- AUTL 2014
- Country
- CRGX United States
- AUTL United Kingdom
- Employees
- CRGX N/A
- AUTL N/A
- Industry
- CRGX
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRGX
- AUTL Health Care
- Exchange
- CRGX Nasdaq
- AUTL Nasdaq
- Market Cap
- CRGX 190.0M
- AUTL 625.4M
- IPO Year
- CRGX 2023
- AUTL 2018
- Fundamental
- Price
- CRGX $4.61
- AUTL $2.49
- Analyst Decision
- CRGX Hold
- AUTL Strong Buy
- Analyst Count
- CRGX 7
- AUTL 5
- Target Price
- CRGX $5.33
- AUTL $9.32
- AVG Volume (30 Days)
- CRGX 2.0M
- AUTL 1.7M
- Earning Date
- CRGX 08-11-2025
- AUTL 08-07-2025
- Dividend Yield
- CRGX N/A
- AUTL N/A
- EPS Growth
- CRGX N/A
- AUTL N/A
- EPS
- CRGX N/A
- AUTL N/A
- Revenue
- CRGX N/A
- AUTL $9,011,000.00
- Revenue This Year
- CRGX $57.81
- AUTL $461.76
- Revenue Next Year
- CRGX N/A
- AUTL $112.66
- P/E Ratio
- CRGX N/A
- AUTL N/A
- Revenue Growth
- CRGX N/A
- AUTL N/A
- 52 Week Low
- CRGX $3.00
- AUTL $1.11
- 52 Week High
- CRGX $25.45
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- CRGX 61.57
- AUTL 73.68
- Support Level
- CRGX $4.32
- AUTL $2.40
- Resistance Level
- CRGX $4.63
- AUTL $2.53
- Average True Range (ATR)
- CRGX 0.15
- AUTL 0.13
- MACD
- CRGX 0.04
- AUTL 0.01
- Stochastic Oscillator
- CRGX 76.44
- AUTL 89.80
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.